ECCO 2025

Personalized dosing of infliximab in moderate to severe…

The importance of endoscopic surveillance – current…

Surgical approaches in IBD – all questions solved?

No treatment choices anymore? Efficacy and safety of…

The perfect dosing of our drugs – data on ustekinumab…

New UC-kids on the block: a IL7 receptor antagonist &…

Anti-TL1a – a new treatment option in IBD and unsolved…

Old vs. new – ustekinumab vs. modern IL23

Combination therapies – on the way to the holy grail?

Comparative efficacy and safety – do we need to…

What is the best treatment goal for moderate to severe…

Urgency – what is hen and what is egg?

Early CD treatment with vedolizumab

Subcutaneous therapy with guselkumab for Crohn's…

The need for early treatment in Crohn’s disease – a…

Kono-S anastomosis is not superior to side-to-side…

Autologous HSCT – still an option for refractory CD?

Dose escalation of vedolizumab in CD is not effective

HSCT autologue – toujours une option pour la maladie de…

Subkutane Therapie mit Guselkumab bei Morbus Crohn und…

La anastomosis Kono-S no es superior a la anastomosis…

Long-term efficacy and safety of a lower obefazimod…

Personalized dosing in acute UC

Appendectomy – a good option for UC

Obefazimod maintenance treatment: a new approach

Subcutaneous therapy with guselkumab for Crohn's…

How to treat UC patients after failure of a s.c.…

Subkutane Therapie mit Guselkumab bei Morbus Crohn und…

Obefazimod in der Erhaltung: Neuer Ansatz

Long-term efficacy and safety of a lower obefazimod…

Erste Kombination von Upadacitinib und Vedolizumab bei…

Comment traiter la RCH après l'échec d'un anti-TNF…

New mode of action for treating UC

Lusvertikimab – a first-in-class IL7 receptor…

SOR102 – a novel oral bispecific antibody in patients…

New treatments – fast forward to the future

A new class of drugs: anti-TL1A antibodies

Eine neue Substanzklassen: Anti-TL1A Antikörper

טיפולים חדשים- fast forward לעתיד

Nouveau mode d'action pour le traitement de la RCH

SOR102 – un nuovo anticorpo bispecifico orale in…

Lusvertikimab – un antagonista del recettore IL7 di…

Association between histologic response and…

Defining radiological healing in perianal fistulising…

Mirikizumab demonstrates rapid improvements in bowel…

Minimal Residual Disease: a new treatment goal in IBD?

Comprehensive approach necessary to treat our patients…

Minimal Residual Disease: ein neuer Endpunkt bei CED?

Was ist der beste Therapieendpunkt bei moderater bis…

Mirikizumab demonstrates rapid improvements in bowel…

Definiendo la curación radiológica en enfermedad de…

Fibre consumption and the risk of developing CD

A low emulsifier diet is a treatment for moderate to…

Tasty&Healthy – the next step towards anti-inflammatory…

Spożycie błonnika a ryzyko zachorowania na chorobę…

ASTRO study established the efficacy of guselkumab…

Etrasimod improves clinical, endoscopic and histologic…

Effectiveness & safety of advanced combination therapy…

PODIUM: effectiveness & safety of 2nd line vedolizumab…

PODIUM: efficacia e sicurezza di Vedolizumab o…

El estudio ASTRO demuestra la eficacia de Guselkumab en…

Eficacia comparativa de infliximab vs. vedolizumab tras…

Infliximab induction fails to reach target drug level…

Dose escalation of primary non-responders is not…

Effectiveness & safety of advanced combination therapy…

Second line treatment for perianal Crohn's disease

Efficacia e sicurezza di una terapia combinata avanzata…

Mancato aumento dei livelli terapeutici di IFX nella…

Zweitlinie bei Crohn-Fisteln

Psychological factors and the risk of IBD flare

Czynniki psychologicne a ryzyko zaostrzenia IBD

αvβ6 – new biomarker in prediciting, staging and…

αvβ6 – ein neuer Biomarker zur Prädiktion, Staging und…

HLA typing – tailoring treatment a step forward?

Identificazione di clonotipi specifici nella malattia…